Junjie Zhang1, Qingjin Yang1, Jian Li1, Yu Zhong1, Lijian Zhang1, Qionglin Huang1, Bin Chen1, Mingming Mo1, Sensen Shen2, Qisheng Zhong3, Huwei Liu2, Chun Cai4. 1. Analysis Center, Zhanjiang Scientific Center of Guangdong Medical University, Zhanjiang, Guangdong, 524023, China. 2. Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, Institute of Analytical Chemistry, College of Chemistry and Molecular Engineering Peking University, Beijing, 100871, China. 3. Shimadzu Global COE for Application and Technical Development, Guangzhou, Guangdong, 510010, China. 4. Analysis Center, Zhanjiang Scientific Center of Guangdong Medical University, Zhanjiang, Guangdong, 524023, China. caichun2006@tom.com.
Abstract
BACKGROUND: Eicosanoids as inflammatory mediators take part in the regulation of disease progression. However, the application of serum eicosanoid in disease progression identification was still uncertain. METHODS: Serum from 52 healthy volunteers, 34 enteritis patients and 55 colorectal cancer (CRC) patients were collected. Ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was used to analyze the change of serum eicosanoids. RESULTS: Of 158 eicosanoids, we found that lower levels of anti-inflammatory eicosanoids 13-HOTrE, 9-HOTrE, DHA, 11-HETE and 12-HHT were observed in enteritis and CRC group compared with healthy group, meanwhile the content of 5-iPF2α-VI as oxidative stress mediator in enteritis and CRC group was greater than that in healthy groups. Moreover, 9-HODE, 13-HODE, 12,13-diHOME, 8-HETE and 15-HETE were dramatically decrease in CRC group compared with non-CRC group. Additionally, the change of 5-, 12- and 15-HETE content in serum sample was associated with progression from healthy to enteritis, finally to CRC. No significant difference between serum eicosanoids and the expression of CerbB-2 and Ki67 were observed. CONCLUSION: Serum eicosanoids might be used as a possible biomarker for identifying among health, enteritis and CRC.
BACKGROUND:Eicosanoids as inflammatory mediators take part in the regulation of disease progression. However, the application of serum eicosanoid in disease progression identification was still uncertain. METHODS: Serum from 52 healthy volunteers, 34 enteritispatients and 55 colorectal cancer (CRC) patients were collected. Ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was used to analyze the change of serum eicosanoids. RESULTS: Of 158 eicosanoids, we found that lower levels of anti-inflammatory eicosanoids 13-HOTrE, 9-HOTrE, DHA, 11-HETE and 12-HHT were observed in enteritis and CRC group compared with healthy group, meanwhile the content of 5-iPF2α-VI as oxidative stress mediator in enteritis and CRC group was greater than that in healthy groups. Moreover, 9-HODE, 13-HODE, 12,13-diHOME, 8-HETE and 15-HETE were dramatically decrease in CRC group compared with non-CRC group. Additionally, the change of 5-, 12- and 15-HETE content in serum sample was associated with progression from healthy to enteritis, finally to CRC. No significant difference between serum eicosanoids and the expression of CerbB-2 and Ki67 were observed. CONCLUSION: Serum eicosanoids might be used as a possible biomarker for identifying among health, enteritis and CRC.
Authors: Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat Journal: Congest Heart Fail Date: 2011-01-27
Authors: Giovanny Rodríguez-Blanco; Peter C Burgers; Lennard J M Dekker; Jan J N Ijzermans; Mark F Wildhagen; Ellen A M Schenk-Braat; Chris H Bangma; Guido Jenster; Theo M Luider Journal: Prostate Date: 2014-01-16 Impact factor: 4.104
Authors: George G Chen; Hu Xu; Janet F Y Lee; Malayannan Subramaniam; Ka L Leung; Su H Wang; Ursula P F Chan; Thomas C Spelsberg Journal: Int J Cancer Date: 2003-12-10 Impact factor: 7.396
Authors: Charles N Serhan; Rong Yang; Kimberly Martinod; Kie Kasuga; Padmini S Pillai; Timothy F Porter; Sungwhan F Oh; Matthew Spite Journal: J Exp Med Date: 2008-12-22 Impact factor: 14.307